Physician profile
Eileen Wang
NPI 1417154956
$1,533.67
in general payments reported to CMS, 2019-2025
14 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $66.98 · 2021: $397 · 2022: $274 · 2023: $107 · 2024: $117 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $441.07 | 2020-2024 | Acthar |
| Allergan, INC. | $267.09 | 2019-2021 | |
| Alcon Vision LLC | $205.93 | 2025 | Tryptyr, Clareon |
| Glaukos Corporation | $118.73 | 2021 | |
| Notal Vision, INC. | $117.86 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $113.62 | 2022-2023 | Tecnis Simplicity, Tecnis Iol |
| Biotissue Holdings INC. | $78.85 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $45.45 | 2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $37.73 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $37.02 | 2025 | Vevye |
| Astellas Pharma US INC | $22.54 | 2024 | Izervay |
| Mallinckrodt Enterprises LLC | $19.03 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.